Lantheus Holdings Completes SPECT Divestiture as Cowen Cuts Price Target by $5
TD Cowen lowered its price target on Lantheus Holdings by $5 ahead of Q4 results while affirming a Buy rating. Lantheus completed its SPECT business sale to SHINE Technologies and will focus on PET radiodiagnostics, microbubble ultrasound contrast and radiopharmaceutical pipeline development.
1. Price Target Revision
TD Cowen revised its financial model ahead of the upcoming fourth-quarter results, lowering its price target on Lantheus Holdings by $5 and reaffirming a Buy rating.
2. SPECT Business Divestiture
On January 2, Lantheus finalized the sale of its Single Photon Emission Computed Tomography business—including diagnostic agents, its North Billerica manufacturing site and Canadian operations—to SHINE Technologies, enabling operational reorganization and redeployment of resources.
3. Strategic Growth Focus
Following the divestiture, Lantheus will concentrate on expanding its PET radiodiagnostic portfolio, microbubble ultrasound contrast agents and invest in its radiopharmaceutical pipeline to fuel long-term growth in precision imaging and targeted therapies.